Company Description
Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops novel therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional metabolic pathways in the United States.
The company’s lead drug candidate is Denifanstat, an oral, once-daily pill and selective FASN inhibitor for the treatment of metabolic dysfunction-associated steatohepatitis.
It also develops TVB-3567, a FASN inhibitor for the treatment of acne; and other oncology programs, such as various solid tumor and glioblastoma.
The company was formerly known as 3-V Biosciences, Inc. and changed its name to Sagimet Biosciences Inc. in August 2019.
Sagimet Biosciences Inc. was incorporated in 2006 and is headquartered in San Mateo, California.
| Country | United States |
| Founded | 2006 |
| IPO Date | Jul 14, 2023 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 14 |
| CEO | David Happel |
Contact Details
Address: 155 Bovet Road, Suite 303 San Mateo, California 94402 United States | |
| Phone | 650 561 8600 |
| Website | sagimet.com |
Stock Details
| Ticker Symbol | SGMT |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Share Class | Class A Shares |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $16.00 |
| CIK Code | 0001400118 |
| CUSIP Number | 786700104 |
| ISIN Number | US7867001049 |
| Employer ID | 20-5991472 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| David A. Happel | Chief Executive Officer, President and Director |
| Thierry Chauche | Chief Financial Officer and Principal Accounting Officer |
| Dr. Eduardo Bruno Martins DPhil, M.D., Ph.D. | Chief Medical Officer |
| Urs Greber Ph.D. | Co-Founder |
| Dr. Lucas Pelkmans Ph.D. | Co-Founder |
| Dr. Marie O'Farrell Ph.D. | Chief Scientific Officer |
| Elizabeth Rozek Esq., J.D. | Chief Legal and Administrative Officer |
| Robert D'Urso | Senior Vice President of New Products |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 20, 2025 | 144 | Filing |
| Nov 14, 2025 | SCHEDULE 13G/A | Filing |
| Nov 13, 2025 | 8-K | Current Report |
| Nov 13, 2025 | 10-Q | Quarterly Report |
| Oct 23, 2025 | 8-K | Current Report |
| Aug 22, 2025 | 8-K | Current Report |
| Aug 14, 2025 | SCHEDULE 13G/A | Filing |
| Aug 14, 2025 | 8-K | Current Report |
| Aug 14, 2025 | 424B5 | Filing |
| Aug 14, 2025 | SCHEDULE 13G | Filing |